Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VeracyteVCYT -3.17%80 Net Cash per Share is $4.82 as of Jun. 2026, which is 64% below its 10-year median of 13.26. GuruFocus rates VCYT with a GF Score™ of 80/100 and a GF Value™ of $38.67 (Fairly Valued). The stock has 5 warning signs investors should review. Among 59 Medical Diagnostics & Research companies, Veracyte ranks worse than 52.54% on this metric.
The historical rank and industry rank for Veracyte's Net Cash per Share or its related term are showing as below:
VCYT'
s Price-to-Net-Cash Range Over the Past 10 Years
Min: 5.98 Med: 13.26 Max: 877
Current: 8.56
During the past 13 years, the highest Price-to-Net-Cash Ratio of Veracyte was 877.00. The lowest was 5.98. And the median was 13.26.
VCYT's Price-to-Net-Cash is ranked worse than 52.54% of 59
companies
in the Medical Diagnostics & Research industry
Industry Median: 8.43
vs VCYT: 8.56
Veracyte (NAS:VCYT) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Veracyte Net Cash per Share Related Terms
Veracyte Net Cash per Share Historical Data
* Premium members only.
The historical data trend for Veracyte's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VCYT vs RDNT, SHC, ADPT: Net Cash per Share Comparison
For the Diagnostics & Research subindustry, Veracyte's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Veracyte Price-to-Net-Cash vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Veracyte's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Veracyte's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Veracyte's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Veracyte (VCYT) has a Net Cash per Share of $4.82 as of Jun. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Veracyte and its competitors. This is 64% below median its historical median of 13.26. Over the past decade, Veracyte's Net Cash per Share has ranged from 5.98 to 877.00. According to the industry distribution chart, Veracyte ranks #31 out of 59 companies in the Medical Diagnostics & Research industry, placing it in the top 52.5%.
Is Veracyte's Net Cash per Share too high?
Veracyte's current Net Cash per Share of $4.82 is 64% below median its 10-year median of 13.26. Over the past 10 years, this metric has ranged from a low of 5.98 to a high of 877.00. The Medical Diagnostics & Research industry median Net Cash per Share is 8.43. Veracyte's value of $4.82 is 42.8% below this industry median. Based on the distribution chart, Veracyte ranks #31 out of 59 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Veracyte has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Veracyte's Net Cash per Share compare to RDNT and SHC?
According to the Medical Diagnostics & Research industry distribution chart, Veracyte ranks #31 out of 59 companies for Net Cash per Share. This places Veracyte in the lower half of its industry. The industry median Net Cash per Share is 8.43. Veracyte's value of $4.82 is 42.8% below this benchmark. Historically, Veracyte's own Net Cash per Share has ranged from 5.98 to 877.00 over the past decade. While the company's 10-year median is 13.26 vs. the industry median of 8.43, Veracyte has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Medical Diagnostics & Research company?
The median Net Cash per Share among Medical Diagnostics & Research companies is 8.43, based on 59 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Veracyte's current Net Cash per Share of $4.82 is 42.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Veracyte and its competitors. For the Medical Diagnostics & Research industry, the median Net Cash per Share is 8.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Veracyte's current Net Cash per Share is $4.82, which is 64% below median its own 10-year median of 13.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veracyte stock overvalued right now?
Based on GuruFocus' analysis, Veracyte (VCYT) is currently considered Fairly Valued. The stock's GF Value™ is $38.67, compared to a current price of $41.25 — trading 6.7% above its estimated fair value. The current Net Cash per Share is $4.82, which is 64% below median its 10-year median of 13.26 and 42.8% below the Medical Diagnostics & Research industry median of 8.43. Veracyte's overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Veracyte (VCYT), the current Net Cash per Share is $4.82 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Veracyte (VCYT) Overvalued in 2026?
Based on GuruFocus' analysis, Veracyte stock appears to be overvalued.
The current stock price of $41.25 is trading 6.7% above its estimated GF Value™ of $38.67.
GuruFocus considers Veracyte to be Fairly Valued.
Key valuation signals for VCYT:
Net Cash per Share: $4.82 (64% below median its 10-year median of 13.26)
GF Value™: $38.67 vs. price of $41.25 (6.7% above fair value)
Industry Position: 42.8% below the Medical Diagnostics & Research median (#31 of 59)
No single metric tells the full story. See the VCYT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
80GF Score
Get the complete analysis for VCYT
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VCYT has been successfully added to your 
